Tvardi Therapeutics (TVRD) Net Income (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Net Income of -$7.6 million for Q1 2026, up 13.12% sequentially from -$8.7 million in Q4 2025, and up 21.16% YoY from -$6.2 million in Q1 2025.
Tvardi Therapeutics (TVRD) Net Income (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Net Income for 14 years, with the latest figure at -$7.6 million in Q1 2026.
- Quarterly Net Income rose 21.16% year-over-year to -$7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$82.2 million (down 120.46% YoY) and the FY2025 annual result came in at -$27.8 million, up 60.73% from the prior year.
- Net Income advanced to -$7.6 million in Q1 2026 per TVRD's latest filing, from -$8.7 million in the prior quarter.
- Over five years, Net Income peaked at -$7.1 million in Q2 2024 and troughed at -$40.0 million in Q3 2025.
- A 5-year average of -$21.9 million and a median of -$26.3 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income slumped 2499.31% in 2022, then soared 78.39% in 2024.
- Over 5 years, Net Income stood at -$31.8 million in 2022, then decreased by 4.12% to -$33.1 million in 2023, then soared by 67.63% to -$10.7 million in 2024, then increased by 18.91% to -$8.7 million in 2025, then climbed by 13.12% to -$7.6 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$7.6 million, -$8.7 million, and -$40.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -6.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.55 Mn |
| Dec 31, 2025 | -8.69 Mn |
| Sep 30, 2025 | -40.00 Mn |
| Jun 30, 2025 | -25.92 Mn |
| Mar 31, 2025 | -9.58 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | -9.88 Mn |
| Jun 30, 2024 | -7.10 Mn |
| Mar 31, 2024 | -31.03 Mn |
| Dec 31, 2023 | -33.11 Mn |
| Sep 30, 2023 | -30.30 Mn |
| Jun 30, 2023 | -32.84 Mn |
| Mar 31, 2023 | -29.15 Mn |
| Dec 31, 2022 | -31.80 Mn |
| Sep 30, 2022 | -26.33 Mn |
| Jun 30, 2022 | -7.45 Mn |
| Mar 31, 2022 | -31.38 Mn |
| Dec 31, 2021 | -33.38 Mn |
| Sep 30, 2021 | -1.01 Mn |
| Jun 30, 2021 | -30.75 Mn |